Menu Search
Equities

Burning Rock Biotech Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6BU0:STU

Burning Rock Biotech Ltd

Actions
  • Price (EUR)25.80
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+348.70%
  • Beta1.3360
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.

  • Revenue in USD (TTM)78.01m
  • Net income in USD-17.54m
  • Incorporated2014
  • Employees674.00
  • Location
    Burning Rock Biotech LtdNo. 5 Xingdao Ring Road NorthInternational Bio IslandGUANGZHOU 510005ChinaCHN
  • Phone+86 18 501641666
  • Websitehttps://www.brbiotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.